Frank McCormick

Frank McCormick

About

Detail

Co-founder
San Francisco, California, United States

Timeline

work
Job
school
Education
folder
Project
auto_stories
Publication

Résumé

Jobs verified_user 0% verified
  • Remedy Plan Therapeutics
    Advisor
    Remedy Plan Therapeutics
    Jan 2016 - Current (10 years 8 months)
  • BridgeBio
    Co-founder
    BridgeBio
    Dec 2015 - Current (10 years 9 months)
  • Olema Oncology
    Director
    Olema Oncology
    Dec 2014 - Dec 2020 (6 years 1 month)
  • Leidos
    Consultant
    Leidos
    Aug 2013 - Current (13 years 1 month)
  • Wellspring Biosciences
    Co-Founder
    Wellspring Biosciences
    Jan 2013 - Current (13 years 8 months)
  • Avidity NanoMedicines
    Co-founder
    Avidity NanoMedicines
    Dec 2012 - Current (13 years 9 months)
  • American Association for Cancer Research
    President
    American Association for Cancer Research
    Apr 2012 - Apr 2013 (1 year 1 month)
    ...
  • UNIVERSITY OF CALIFORNIA SAN FRANCISCO
    Professor
    UNIVERSITY OF CALIFORNIA SAN FRANCISCO
    Jul 1998 - Current (28 years 2 months)
  • Onyx Pharmaceuticals Inc an Amgen subsidiary
    Founder and CSO
    Onyx Pharmaceuticals Inc an Amgen subsidiary
    Apr 1992 - Jun 1997 (5 years 3 months)
    Founder
  • Chiron Corporation
    VP Research
    Chiron Corporation
    Oct 1991 - Apr 1992 (7 months)
    VP
Education verified_user 0% verified
  • University of Cambridge
    Ph D, Biochemistry
    University of Cambridge
    Jan 1972 - Dec 1975 (4 years)
  • University of Birmingham
    B. Sc, Biochemistry
    University of Birmingham
    Jan 1969 - Dec 1972 (4 years)
Projects (professional or personal) verified_user 0% verified
    Publications verified_user 0% verified
    • C
      Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Onc
      Cell Reports
      Jul 2020
      Sprouty-related, EVH1 domain-containing (SPRED) proteins negatively regulate RAS/mitogen-activated protein kinase (MAPK) signaling following growth factor stimulation. This inhibition of RAS is thought to occur primarily through SPRED1 binding and recruitment of neurofibromin, a RasGAP, to the plasma membrane. Here, we report the structure of neurofibromin (GTPase-activating protein [GAP]-related domain) complexed with SPRED1 (EVH1 domain) and KRAS. The structure provides insight into how the membrane targeting of neurofibromin by SPRED1 allows simultaneous interaction with activated KRAS. SPRED1 and NF1 loss-of-function mutations occur across multiple cancer types and developmental diseases. Analysis of the neurofibromin-SPRED1 interface p
    • N
      Dual gene activation and knockout screen reveals directional dependencies in genetic networks
      Nature Biotechnology
      Jan 2018
      Understanding the direction of information flow is essential for characterizing how genetic networks affect phenotypes. However, methods to find genetic interactions largely fail to reveal directional dependencies. We combine two orthogonal Cas9 proteins from Streptococcus pyogenes and Staphylococcus aureus to carry out a dual screen in which one gene is activated while a second gene is deleted in the same cell. We analyze the quantitative effects of activation and knockout to calculate genetic interaction and directionality scores for each gene pair. Based on the results from over 100,000 perturbed gene pairs, we reconstruct a directional dependency network for human K562 leukemia cells and demonstrate how our approach allows the determina
    This is a community-created genome.